TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average +0.87%-1.68%+41.59%+179.99% 25.95B
Weighted average by Cap. +1.48%-1.67%+41.46%+139.49%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock